The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck has agreed to a $10-billion buyout of Verona Pharma and its first-in-class, potential COPD blockbuster Ohtuvayre.

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma's new chronic ...

Merck & Co. shares were climbing 3.1% in afternoon trading after the pharmaceutical giant announced a $10 billion deal to acquire respiratory-disease specialist Verona Pharma PLC.

TUPELO – A mid-afternoon pursuit in late May ended in late June with the arrest of a Verona man.